We are live on ! Find out more
KERX

Keryx Biopharmaceuticals Inc
KERX

Delisted

KERX was delisted on the 12th of December, 2018.

132 hedge funds and large institutions have $278M invested in Keryx Biopharmaceuticals Inc in 2018 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 38 increasing their positions, 32 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

47% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 15

19% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 32

6% more funds holding

Funds holding: 125132 (+7)

0% less call options, than puts

Call options by funds: $2.21M | Put options by funds: $2.22M

11% less capital invested

Capital invested by funds: $313M → $278M (-$35.3M)

Holders
132
Holders Change
+7
Holders Change %
+5.6%
% of All Funds
3.02%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
22
Increased
38
Reduced
32
Closed
15
Calls
$2.21M
Puts
$2.22M
Net Calls
-$6K
Net Calls Change
+$1.92M
Name Holding Trade Value Shares
Change
Change in
Stake
NSAM
101
North Star Asset Management
Wisconsin
$41K +$52.6K +10,800 New
Tudor Investment Corp
102
Tudor Investment Corp
Connecticut
$41K +$53.5K +10,980 New
Prudential Financial
103
Prudential Financial
New Jersey
$40K +$1.12K +230 +2%
BFM
104
Boothbay Fund Management
New York
$39K +$51K +10,477 New
Canada Life
105
Canada Life
Manitoba, Canada
$38K
BCM
106
BlueCrest Capital Management
Jersey
$38K +$49K +10,058 New
AIM
107
Advantage Investment Management
Iowa
$34K -$407K -83,492 -90%
CA
108
Centerpoint Advisors
Massachusetts
$32K
AIP
109
Ameritas Investment Partners
Nebraska
$29K
Zurich Cantonal Bank
110
Zurich Cantonal Bank
Switzerland
$28K
Royal Bank of Canada
111
Royal Bank of Canada
Ontario, Canada
$23K +$11.4K +2,346 +64%
SEI Investments
112
SEI Investments
Pennsylvania
$17K +$346 +71 +2%
APA
113
American Portfolios Advisors
New York
$15K
ClearBridge Investments
114
ClearBridge Investments
New York
$15K -$1.31K -269 -6%
Simplex Trading
115
Simplex Trading
Illinois
$14K +$19.2K +3,953 New
LTFS
116
Ladenburg Thalmann Financial Services
Florida
$12K
Northwestern Mutual Wealth Management
117
Northwestern Mutual Wealth Management
Wisconsin
$11K +$14.1K +2,900 New
AF
118
Allworth Financial
California
$8K
FHA
119
Flagship Harbor Advisors
Massachusetts
$7K +$9.73K +1,999 New
PIA
120
Piedmont Investment Advisors
North Carolina
$6K +$7.99K +1,641 New
CLM
121
ClearBridge LLC (Maryland)
Maryland
$5.48K -$5.83M -1,197,935 -45%
Nisa Investment Advisors
122
Nisa Investment Advisors
Missouri
$5K
BA
123
Bristol Advisors
Pennsylvania
$4K
JCM
124
Jacobi Capital Management
Pennsylvania
$4K
MAM
125
Meeder Asset Management
Ohio
$3.6K +$3.7K +760 +384%

KERX Hedge Fund Activity: Q2 2018 in Review

132 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in Keryx Biopharmaceuticals Inc (KERX) for Q2 2018, worth a combined $278M — down 11% from $313M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new KERX positions and 15 closed out — a net gain of 7 holders — while 38 added to existing stakes and 32 trimmed.

The largest buyer was PKO Investment Management Joint-Stock, opening a new position worth an estimated $7.16M. The largest seller was ClearBridge LLC (Maryland), cutting an estimated $5.83M.

  • 132 institutional investors held Keryx Biopharmaceuticals Inc (KERX) as of Q2 2018, up from 125 in Q1 2018.
  • Funds reported $278M of Keryx Biopharmaceuticals Inc stock for Q2 2018, down 11% quarter-over-quarter.
  • 22 funds opened new Keryx Biopharmaceuticals Inc positions in Q2 2018 and 15 closed out, a net change of +7 holders.
  • The largest Keryx Biopharmaceuticals Inc buyer in Q2 2018 was PKO Investment Management Joint-Stock, an estimated $7.16M added.
  • The largest Keryx Biopharmaceuticals Inc seller in Q2 2018 was ClearBridge LLC (Maryland), an estimated $5.83M sold.

Based on aggregated 13F filings for Q2 2018.